series-f
(2)
Andrew Rubin
Andrew Rubin is the CEO and co-founder of Illumio, the company that pioneered Zero Trust Segmentation - the idea that once a breach happens (and it will), you stop it from spreading. A Brooklyn native who built his career through sales, he founded Illumio in 2013 and scaled it to a $2.75B valuation with $225M in Series F funding, backed by Andreessen Horowitz, Accel, General Catalyst, and investors including Marc Benioff and John W. Thompson. Named to Goldman Sachs' '100 Most Intriguing Entrepreneurs' seven times, he earned EY Bay Area Entrepreneur of the Year in 2024 and remains one of cybersecurity's most vocal advocates for rethinking how organizations think about inevitable breaches.
Nathaniel Fernhoff
Nathaniel Fernhoff is the CEO and Co-founder of Orca Bio, a late-stage biotechnology company headquartered in Menlo Park, California, developing high-precision allogeneic T-cell immunotherapies to treat blood cancers and autoimmune diseases. Holding a Ph.D. in Molecular and Cell Biology from UC Berkeley and dual Bachelor's degrees in Biological Sciences and Mathematics from Stanford, Fernhoff co-founded Orca Bio in 2016 based on decades-old Stanford research. He rose from Chief Scientific Officer to CEO in May 2025, leading the company through a landmark Phase 3 clinical trial for Orca-T - showing 78% survival free from chronic graft-versus-host disease versus 38% for standard-of-care - a BLA submission under FDA Priority Review, and a $250M Series F round bringing total funding to over $625M. With a 100,000-square-foot manufacturing facility in Sacramento capable of producing ~3,000 cell therapy products per year, Fernhoff is steering Orca Bio toward potential commercialization and a cure for blood diseases without compromise.